Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples....more
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to supports the development of new exploratory research in cancer diagnosis, treatment, imaging,...more
Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples....more
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological...more
The purpose of this notice of funding opportunity (NOFO) is to support multidisciplinary research programs focused on discovery to early development research to inform new approaches to prevent,...more
This announcement invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system....more
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award...more
NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting...more
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions. Specifically, this NOFO solicits R33...more
Digbeth in Birmingham, England has been appointed as the new social enterprise quarter. Social enterprises are sprouting up in the area, comprising of 57 of these businesses flanked between High Gate and Hurst Street.